|
DNA May Predict
Benefit of Lung Cancer Treatment
(3/15/07)
A genetic test holds promise for identifying
which early-stage lung cancer patients would benefit from
chemotherapy and which would be better off without it,
researchers report.
The
test might also work in a similar way for patients with other
malignancies, the experts said.
More...
High Tech Detectives
Screen Thousands Of Genes, Proteins To Solve Puzzle Of Lung
Disease (10/23/06)
Recent advances in computer and imaging technology
allow the scanning of tens of thousands of genes and proteins in little
more than a blink of an eye. This high speed technology has already
produced advances in the understanding of disease, including lung disease,
and the already blistering pace is picking up.
More...
Gene Signature Could Revolutionize Cancer Care (6/3/05)
Scientists have identified an 11-gene "signature" in
cancer tumors that appears to predict prognosis in at least 10 types of
malignancies. If it passes further testing, the signature may help
doctors and patients decide on therapies that suit particular cancer
types, a giant step forward in the emerging era of tailored treatments.
More...
Australians Prepare
for Meso Epidemic with Breakthrough Diagnostic Test
(9/16/03)
Melbourne researchers have achieved a breakthrough
that promises to significantly improve the treatment of people with
asbestos-related cancer, which is tipped to reach epidemic proportions in
a decade.
More...
MG98's
Preclinical Antitumor Activity and Safety, and Phase 1 Clinical
Profile Demonstrated in Two Mesothelioma Patients
(11/2/01)
MG98 is a second-generation antisense oligonucleotide that inhibits
the enzyme DNA methyltransferase.
More...
Preclinical
Data of Introgen's INGN 241 Demonstrate Broad
Anti-Cancer Activity In Multiple Tumor Types as Monotherapy and in
Combination; Update on Gene Therapy Research at MDA under Dr. Roy
Smythe. (6/14/01)
Introgen
Therapeutics, Inc. today reported preclinical findings demonstrating that INGN 241, an
Adenoviral vector encoding the mda-7 gene, is a novel cytokine family member that exhibits
broad anticancer activity.
More...
Australia
Doctors: Gene Therapy (IL-12) Retards Mesothelioma
in Mice But Causes Side Effects (9/27/99)
Gene therapy that boosts the body's
immune system appears to be effective at preventing mesothelioma
-- a lethal tumor of the lining of the chest -- from growing in
mice, according to Australian researchers.
More...
Brave 49 Year Old
Woman
Shows Response to Gene Therapy, But Tumors Return. New
Orleans, LA (8/3/99)
Patricia Johnson is a 49 year old woman who was diagnosed
with mesothelioma in August of 1998. She lives in New Orleans, Louisiana. Her doctor is
Dr. Paul Schwarzenberger, who is the principal investigator of the Gene
Therapy Program at the Louisiana State University Medical Center
in New Orleans.
More...
Antitumor
Activity With Gene Modified Tumor Cells: Dr. Paul
Schwarzenberger (8/14/98)
Since it is uniformly fatal and
kills by local spread, investigators have proposed that
malignant mesotthelioma is a good target for novel treatment
approaches, such as gene therapy.
More...
Son of Insulator
with MM Helps Father Enroll in Gene Therapy Program at LSU.
New Orleans,
LA (12/10/97)
My name is Todd Armstrong. On
February 24th, 1997, my Dad, Bill Armstrong, was diagnosed with
malignant mesothelioma (M.M.). I wanted to try to help my dad
find some treatment for this, so I started looking on the
Internet.
More...
Gene
Therapy
Phase I Study at
LSU
Medical
Center: Dr. Paul Schwarzenberger (12/97)
Because of the dismal prognosis for
patients with malignant mesothelioma, a new mode of treatment is
desperately needed. A promising area of research into the
treatment of various malignancies is gene therapy.
More...
University of Pennsylvania Study
(1996) The University of Pennsylvania
in Philadelphia has developed a new "gene therapy" protocol that is
designed to weaken the tumor cells. In the first phase, the patient
takes biopsy samples from the lung and places a tube into the chest
cavity near the tumors.
Click
here for
A Conversation
Between Roger G.
Worthington and Dr. Daniel Sterman - August 20th, 1996 Regarding: The ongoing clinical trials at the University of Pennsylvania
|